Repaglinide has 39 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clopidogrel, Clopidogrel Bisulfate, Gemfibrozil. Patients taking Repaglinide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 39
- Contraindicated
- 3
- Major
- 4
- Moderate
- 30
Contraindicated (3)
- Repaglinide + Clopidogrel— Clopidogrel increases repaglinide exposure by 3.9- to 5.1-fold. Avoid concomitant use.
- Repaglinide + Clopidogrel Bisulfate— Clopidogrel increases repaglinide exposure 3.9-5.1 fold. Avoid concomitant use or adjust dose and monitor closely.
- Repaglinide + Gemfibrozil— Gemfibrozil significantly increased repaglinide exposures by 8.1 fold. Do not administer repaglinide to patients receivi…
Major (4)
- Repaglinide + Atazanavir— Atazanavir without ritonavir is not recommended when coadministered with repaglinide due to CYP2C8 inhibition and narrow…
- Repaglinide + Atazanavir And Cobicistat— Repaglinide is highly dependent on CYP2C8 for clearance with narrow therapeutic index. EVOTAZ use is not recommended wit…
- Repaglinide + Cyclosporine— Cyclosporine increased repaglinide exposures by 2.5 fold. Limit daily maximum dose to 6 mg and increase glucose monitori…
- Repaglinide + Deferasirox— Deferasirox increases exposure of repaglinide. Consider repaglinide dose reduction and monitor blood glucose levels.
Moderate (30)
- Repaglinide + Atazanavir Sulfate— Atazanavir without ritonavir is not recommended when coadministered with repaglinide due to CYP2C8 inhibition and narrow…
- Repaglinide + Barbiturates— CYP3A4 and CYP2C8 inducers. Repaglinide dose increase and increased glucose monitoring may be required during concomitan…
- Repaglinide + Carbamazepine— CYP3A4 and CYP2C8 inducer. Repaglinide dose increases and increased glucose monitoring may be required.
- Repaglinide + Clarithromycin— Antibacterial agent that inhibits CYP3A4. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Clozapine— Atypical antipsychotic that may decrease blood glucose lowering effect. Repaglinide dose increases and increased glucose…
- Repaglinide + Danazol— May decrease blood glucose lowering effect of repaglinide. Dose increases and increased glucose monitoring may be requir…
- Repaglinide + Disopyramide— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Eltrombopag— OATP1B1 substrate; eltrombopag may increase exposure. Monitor closely and consider dose reduction if appropriate.
- Repaglinide + Eltrombopag Olamine— OATP1B1 substrate; monitor for excessive exposure and consider dose reduction if appropriate.
- Repaglinide + Erythromycin— Antibacterial agent that inhibits CYP3A4. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Fluoxetine— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Glucagon— May decrease blood glucose lowering effect of repaglinide. Dose increases and increased glucose monitoring may be requir…
- Repaglinide + Isoniazid— May decrease blood glucose lowering effect of repaglinide. Dose increases and increased glucose monitoring may be requir…
- Repaglinide + Itraconazole— Antifungal agent that inhibits CYP3A4. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Ketoconazole— Antifungal agent that inhibits CYP3A4. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Leflunomide— Exposure to repaglinide may be increased when coadministered with leflunomide. Monitor and adjust dose as required.
- Repaglinide + Leflunomide And Diclofenac Sodium Gel— Exposure of repaglinide may be increased in patients taking leflunomide. Monitor and adjust dose as required.
- Repaglinide + Montelukast— CYP2C8 inhibitor. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Niacin— May decrease blood glucose lowering effect of repaglinide. Dose increases and increased glucose monitoring may be requir…
- Repaglinide + Octreotide— Somatostatin analog that may increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring…
- Repaglinide + Olanzapine— Atypical antipsychotic that may decrease blood glucose lowering effect. Repaglinide dose increases and increased glucose…
- Repaglinide + Paclitaxel— CYP2C8 substrate; caution should be exercised when administering paclitaxel concomitantly.
- Repaglinide + Pentoxifylline— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Pramlintide— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Propoxyphene— May increase risk of hypoglycemia. Repaglinide dose reductions and increased glucose monitoring may be required.
- Repaglinide + Rifampin— CYP3A4 and CYP2C8 inducer. Repaglinide dose increases and increased glucose monitoring may be required.
- Repaglinide + Sulfamethoxazole And Trimethoprim— BACTRIM potentiates oral hypoglycemic effects of repaglinide. Additional blood glucose monitoring warranted.
- Repaglinide + Tecovirimat Monohydrate— TPOXX increases repaglinide concentration. Monitor blood glucose and hypoglycemic symptoms when co-administered.
- Repaglinide + Teriflunomide— Teriflunomide may increase exposure of repaglinide. Monitor patients and adjust dose as required.
- Repaglinide + Trimethoprim— CYP2C8 inhibitor. Repaglinide dose reductions and increased glucose monitoring may be required.